DENVER — Four studies presented at the American Academy of Neurology annual meeting show improvements in patients with spinocerebellar ataxia who take troriluzole. “SCAs [spinocerebellar ...

While many people will have DNA repetitions seen in patients with spinocerebellar ataxia, this does not guarantee the onset of the disease at any point in life. However, those with amyotrophic ...

ANN ARBOR -- An abnormality discovered by University of Michigan researchers in mice with Spinocerebellar Ataxia type 3 could represent a target for therapy. In a paper published this week in the ...

The report provides a detailed analysis of the current spinocerebellar ataxia marketed drugs and late-stage pipeline drugs, ...

Seelos Therapeutics Inc (NASDAQ: SEEL) temporarily pauses additional enrollment of patients in the SLS-005-302 study in spinocerebellar ataxia type 3 (SCA3). Patients already enrolled will ...

More information: Tomohiko Ishihara et al, L-arginine in patients with spinocerebellar ataxia type 6: a multicentre, ...

According to Biohaven, the FDA’s decision on the NDA is expected during the 3rd quarter of 2025. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...

Patients with Spinocerebellar Ataxia often experience difficulties with walking, hand-eye coordination, speech (dysarthria), and in some cases, vision and cognitive function. There are more than ...

for troriluzole for the treatment of adult patients with spinocerebellar ataxia (SCA) and has granted Priority Review. This designation is assigned to applications for drugs that would offer a ...

Forty patients with SCA6 were recruited and ... reliable evidence for the use of L-arginine as a treatment for spinocerebellar ataxia and may clarify its long-term safety profile in this population.

But 15 years ago, he met a patient whom he thought could be the key to solving a decade-long mystery. The patient had spinocerebellar ataxia type 4 (SCA4), a progressive neurodegenerative disease that ...